BioSpace News Archive

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2023.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, announced that the Company will participate in fireside chats at the following upcoming investor events.

LTS LOHMANN Therapie-Systeme AG announced that its customer Coherus BioSciences, Inc has launched its UDENYCA® on-body injector utilizing the LTS Sorrel™ wearable drug delivery platform.) UDENYCA® is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chief Executive Officer Dr. Matt Coffey will present a corporate overview at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference.

Lavie Bio Ltd. Ltd. announced that it has successfully secured the second-half advance payment of $2.5 million after meeting Corteva’s (NYSE: CTVA) licensing agreement requirements.

Ginkgo Bioworks announced the creation of the Ginkgo Technology Network - a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.

Today, Ginkgo Bioworks announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines.

Covalon Technologies Ltd. today announced its fiscal 2024 first quarter results for the period ended December 31, 2023.